Bristol-Myers and Pfizer Gain Japanese Approval for Eliquis

The Japanese Ministry of Health, Labor, and Welfare, the equivalent of the U.S. FDA, approved Bristol-Myers Squibb (NYSE: BMY  ) and Pfizer's (NYSE: PFE  ) Eliquis for the prevention of strokes and blood clots in patients with nonvalvular atrial fibrillation, a type of irregular heartbeat.

Eliquis reduced the risk of stroke, major bleeding, and all causes of death compared with warfarin. Eliquis' competitor is available as a generic but is difficult for doctors to dose properly because the dosage requirements vary among patients and there's a small range in which the drug works -- too little and it doesn't work; too much and the drug causes bleeding .

This is the third approval for Eliquis in nonvalvular atrial fibrillation within six weeks; the drug was recently approved in the EU and Canada. In the U.S., the FDA issued a Complete Response Letter in June, requesting additional data and verification from ARISTOTLE, the pivotal clinical trial supporting Eliquis' use in atrial fibrillation. The companies have already reapplied, and the FDA has set a goal to respond on or before March 17, 2013.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2169297, ~/Articles/ArticleHandler.aspx, 9/20/2014 8:18:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement